Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds

Akitomo Sugawara, Jun Nakashima, Etsuo Kunieda, Hirohiko Nagata, Ryuichi Mizuno, Atsuya Takeda, Satoshi Seki, Yutaka Shiraishi, Ryuichi Kouta, Mototsugu Oya, Naoyuki Shigematsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The dose received by 90% of the prostate volume (D90) is the key parameter of dosimetric analysis in prostate brachytherapy. The aim of this analysis was to identify preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 210 patients who underwent transperineal interstitial prostate brachytherapy with loose 125I seeds for clinical T1/T2 prostate cancer at our institution. Patients who received supplemental external-beam radiation therapy were excluded. One hundred and nine patients (51.9%) received neoadjuvant hormonal therapy (NHT). One month after seed implantation, postimplant computed tomography and dosimetric analysis were performed. Univariate and multivariate analyses were carried out to identify preimplant factors affecting postimplant prostate D90. The postimplant prostate D90 values ranged from 123.3 to 234.1 Gy (mean ± standard error, 177.1 ± 1.4 Gy). Postimplant prostate D90 differed significantly between patients who had and had not undergone NHT (P = 0.001). In addition, simple regression analyses showed positive correlations with the estimated preimplant prostate D90, preimplant prostate volume by transrectal ultrasound (TRUS), total radioactivity, number of needles, and number of seeds. On stepwise multiple regression analysis, postimplant prostate D90 showed significant negative correlations with NHT and preimplant prostate volume by TRUS, and a significant positive correlation with total radioactivity. In conclusion, NHT, preimplant prostate volume by TRUS, and total radioactivity are significant preimplant factors affecting postimplant prostate D90 in prostate cancer patients treated with transperineal interstitial prostate brachytherapy with loose 125I seeds.

Original languageEnglish
Pages (from-to)89-94
Number of pages6
JournalKeio Journal of Medicine
Volume61
Issue number3
Publication statusPublished - 2012 Sep

Fingerprint

Brachytherapy
Prostate
Seeds
Neoadjuvant Therapy
Radioactivity
Prostatic Neoplasms
Regression Analysis
Needles

Keywords

  • I
  • Brachytherapy
  • Dosimetry
  • Prostate cancer
  • Seed

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. / Sugawara, Akitomo; Nakashima, Jun; Kunieda, Etsuo; Nagata, Hirohiko; Mizuno, Ryuichi; Takeda, Atsuya; Seki, Satoshi; Shiraishi, Yutaka; Kouta, Ryuichi; Oya, Mototsugu; Shigematsu, Naoyuki.

In: Keio Journal of Medicine, Vol. 61, No. 3, 09.2012, p. 89-94.

Research output: Contribution to journalArticle

Sugawara, Akitomo ; Nakashima, Jun ; Kunieda, Etsuo ; Nagata, Hirohiko ; Mizuno, Ryuichi ; Takeda, Atsuya ; Seki, Satoshi ; Shiraishi, Yutaka ; Kouta, Ryuichi ; Oya, Mototsugu ; Shigematsu, Naoyuki. / Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. In: Keio Journal of Medicine. 2012 ; Vol. 61, No. 3. pp. 89-94.
@article{be576066d222498fa1a2dfd1cc86ddc5,
title = "Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds",
abstract = "The dose received by 90{\%} of the prostate volume (D90) is the key parameter of dosimetric analysis in prostate brachytherapy. The aim of this analysis was to identify preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 210 patients who underwent transperineal interstitial prostate brachytherapy with loose 125I seeds for clinical T1/T2 prostate cancer at our institution. Patients who received supplemental external-beam radiation therapy were excluded. One hundred and nine patients (51.9{\%}) received neoadjuvant hormonal therapy (NHT). One month after seed implantation, postimplant computed tomography and dosimetric analysis were performed. Univariate and multivariate analyses were carried out to identify preimplant factors affecting postimplant prostate D90. The postimplant prostate D90 values ranged from 123.3 to 234.1 Gy (mean ± standard error, 177.1 ± 1.4 Gy). Postimplant prostate D90 differed significantly between patients who had and had not undergone NHT (P = 0.001). In addition, simple regression analyses showed positive correlations with the estimated preimplant prostate D90, preimplant prostate volume by transrectal ultrasound (TRUS), total radioactivity, number of needles, and number of seeds. On stepwise multiple regression analysis, postimplant prostate D90 showed significant negative correlations with NHT and preimplant prostate volume by TRUS, and a significant positive correlation with total radioactivity. In conclusion, NHT, preimplant prostate volume by TRUS, and total radioactivity are significant preimplant factors affecting postimplant prostate D90 in prostate cancer patients treated with transperineal interstitial prostate brachytherapy with loose 125I seeds.",
keywords = "I, Brachytherapy, Dosimetry, Prostate cancer, Seed",
author = "Akitomo Sugawara and Jun Nakashima and Etsuo Kunieda and Hirohiko Nagata and Ryuichi Mizuno and Atsuya Takeda and Satoshi Seki and Yutaka Shiraishi and Ryuichi Kouta and Mototsugu Oya and Naoyuki Shigematsu",
year = "2012",
month = "9",
language = "English",
volume = "61",
pages = "89--94",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "3",

}

TY - JOUR

T1 - Preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds

AU - Sugawara, Akitomo

AU - Nakashima, Jun

AU - Kunieda, Etsuo

AU - Nagata, Hirohiko

AU - Mizuno, Ryuichi

AU - Takeda, Atsuya

AU - Seki, Satoshi

AU - Shiraishi, Yutaka

AU - Kouta, Ryuichi

AU - Oya, Mototsugu

AU - Shigematsu, Naoyuki

PY - 2012/9

Y1 - 2012/9

N2 - The dose received by 90% of the prostate volume (D90) is the key parameter of dosimetric analysis in prostate brachytherapy. The aim of this analysis was to identify preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 210 patients who underwent transperineal interstitial prostate brachytherapy with loose 125I seeds for clinical T1/T2 prostate cancer at our institution. Patients who received supplemental external-beam radiation therapy were excluded. One hundred and nine patients (51.9%) received neoadjuvant hormonal therapy (NHT). One month after seed implantation, postimplant computed tomography and dosimetric analysis were performed. Univariate and multivariate analyses were carried out to identify preimplant factors affecting postimplant prostate D90. The postimplant prostate D90 values ranged from 123.3 to 234.1 Gy (mean ± standard error, 177.1 ± 1.4 Gy). Postimplant prostate D90 differed significantly between patients who had and had not undergone NHT (P = 0.001). In addition, simple regression analyses showed positive correlations with the estimated preimplant prostate D90, preimplant prostate volume by transrectal ultrasound (TRUS), total radioactivity, number of needles, and number of seeds. On stepwise multiple regression analysis, postimplant prostate D90 showed significant negative correlations with NHT and preimplant prostate volume by TRUS, and a significant positive correlation with total radioactivity. In conclusion, NHT, preimplant prostate volume by TRUS, and total radioactivity are significant preimplant factors affecting postimplant prostate D90 in prostate cancer patients treated with transperineal interstitial prostate brachytherapy with loose 125I seeds.

AB - The dose received by 90% of the prostate volume (D90) is the key parameter of dosimetric analysis in prostate brachytherapy. The aim of this analysis was to identify preimplant factors affecting prostate D90 after transperineal interstitial prostate brachytherapy with loose 125I seeds. We reviewed the records of 210 patients who underwent transperineal interstitial prostate brachytherapy with loose 125I seeds for clinical T1/T2 prostate cancer at our institution. Patients who received supplemental external-beam radiation therapy were excluded. One hundred and nine patients (51.9%) received neoadjuvant hormonal therapy (NHT). One month after seed implantation, postimplant computed tomography and dosimetric analysis were performed. Univariate and multivariate analyses were carried out to identify preimplant factors affecting postimplant prostate D90. The postimplant prostate D90 values ranged from 123.3 to 234.1 Gy (mean ± standard error, 177.1 ± 1.4 Gy). Postimplant prostate D90 differed significantly between patients who had and had not undergone NHT (P = 0.001). In addition, simple regression analyses showed positive correlations with the estimated preimplant prostate D90, preimplant prostate volume by transrectal ultrasound (TRUS), total radioactivity, number of needles, and number of seeds. On stepwise multiple regression analysis, postimplant prostate D90 showed significant negative correlations with NHT and preimplant prostate volume by TRUS, and a significant positive correlation with total radioactivity. In conclusion, NHT, preimplant prostate volume by TRUS, and total radioactivity are significant preimplant factors affecting postimplant prostate D90 in prostate cancer patients treated with transperineal interstitial prostate brachytherapy with loose 125I seeds.

KW - I

KW - Brachytherapy

KW - Dosimetry

KW - Prostate cancer

KW - Seed

UR - http://www.scopus.com/inward/record.url?scp=84867735560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867735560&partnerID=8YFLogxK

M3 - Article

C2 - 23018491

AN - SCOPUS:84867735560

VL - 61

SP - 89

EP - 94

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 3

ER -